Company profile for D3 Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

D3 Bio is a biotechnology firm with a global scope, dedicated to the development and registration of cutting-edge medicines in the fields of oncology and immunology. Our approach to new medicine development sets us apart. Rather than solely beginning with scientific research in the lab, we first identify the most pressing unmet needs of patients and the market. We focus on areas where current standard-of-care treatments fail t...
D3 Bio is a biotechnology firm with a global scope, dedicated to the development and registration of cutting-edge medicines in the fields of oncology and immunology. Our approach to new medicine development sets us apart. Rather than solely beginning with scientific research in the lab, we first identify the most pressing unmet needs of patients and the market. We focus on areas where current standard-of-care treatments fail to deliver satisfactory clinical outcomes.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
324 (Room 324), 88 MeiLiang Road, MaShan Street, Binhu District, Wuxi (and Sha...
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/d3-bio-secures-108-million-in-series-b-financing-to-advance-global-clinical-programs-302636690.html

PR NEWSWIRE
10 Dec 2025

https://www.prnewswire.com/news-releases/d3-bio-inc-announces-fda-breakthrough-therapy-designation-and-orphan-drug-designation-for-d3s-001-for-the-treatment-of-patients-with-kras-g12c-mutated-cancers-302540808.html

PR NEWSWIRE
28 Aug 2025

https://www.businesswire.com/news/home/20250429337560/en/D3-Bio-Announces-Nature-Medicine-Publication-and-AACR-2025-Presentation-Highlighting-D3S-001-as-a-Next-Generation-KRAS-G12C-Inhibitor-with-Best-in-Class-Potential

BUSINESSWIRE
29 Apr 2025

https://www.businesswire.com/news/home/20241125088779/en

BUSINESSWIRE
25 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty